IP Verse

Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist - EP4011915B8

PatentPatent Analysis

EP4011915

REGENERON PHARMACEUTICALS
Application Number
EP21199451A
Filing Date
Aug 20, 2013
Status
Granted And Under Opposition
Sep 8, 2023
Grant Date
Nov 15, 2023
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP4252857B1
EP3506931B1
EP3889181B1

Bibliography

The patent EP4011915B8 was granted to Regeneron Pharmaceuticals on Nov 15, 2023 following the initial filing on Aug 20, 2013 under the application number EP21199451A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

HAMPTON KNOWLESJul 11, 2024ADMISSIBLE
BOULT WADE TENNANTJul 10, 2024ADMISSIBLE
SECERNAJul 10, 2024ADMISSIBLE
MICHALSKI HUTTERMANN & PARTNER PATENTANWALTE MBBJul 8, 2024ADMISSIBLE
DR H ULRICH DORRIESJul 3, 2024ADMISSIBLE
LUIGIOct 11, 2023ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents